Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can virtual reality and a blood pressure drug crush cigarette cravings?

NCT ID NCT03083353

Symptom relief Sponsor: Jasper A. Smits Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a drug called isradipine, combined with virtual reality scenes of smoking, could lower cigarette cravings. 78 daily smokers took part. The goal was to see if this approach could help people quit smoking by reducing their urge to smoke when faced with triggers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

78 people

The number who actually took part.

Started

Jan 2020

Finished

Jun 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. 18-65 years old; 2. Willing and able to provide informed consent, attend all study visits, and comply with the protocol; 3. Daily smoker for at least one year; and 4. Currently smoke an average of at least 5 cigarettes per day. Exclusion Criteria: 1. Current diagnosis of a psychotic, eating, developmental or bipolar disorder, or significant suicide risk; 2. Current treatment for smoking cessation or use of other nicotine products, including e-cigarettes; 3. Exclusion criteria related to isradipine administration: (a) known allergy or sensitivity to isradipine, (b) hypertension, (c) congestive heart failure, (d) any type of liver disease, (e) current pregnancy, (f) women of childbearing potential who are not using medically accepted forms of contraception, (g) current use of Rifampin, which decreases the availability of calcium channel blockers, or of Tagamet, which can increase hypotensive effects and inhibit hepatic metabolism of isradipine, (h) any other significant medical condition that increases risk, as determined by the study physician; 4. Significant vision problems that would prevent engagement with the 360° video environment; and 5. Past six month substance use disorder, other than nicotine use disorder, assessed by structured interview.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Craving are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cigarette Smoking nicotine dependence Smoking Smoking Cessation Smoking Reduction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Craving Nicotine dependence Smoking ( cigarette) Smoking behaviors Smoking cessation Smoking reduction

Contacts and locations

Locations

  • University of Texas at Austin

    Austin, Texas, 78712, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.